Compare Abeona Therapeutics Inc (ABEO) vs Allegion PLC (ALLE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Allegion PLC — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Allegion PLC trades at $135.08 (market cap $11.97B). The key difference: Allegion PLC is far larger — about 32.1× Abeona Therapeutics Inc's market cap, and Allegion PLC pays a 1.52% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ALLE | |
|---|---|---|
Market Cap | $373.32M | $11.97B |
Sector | Health | Industrials |
52-Week High | $7.23 | $179.77 |
52-Week Low | $4.17 | $125.65 |
Enterprise Value | $228.22M | $13.69B |
Dividend Yield | — | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ALLE trades at $139.32, down 0.9% on the day, with a bullish technical signal and strong fundamentals including a 15.24% net margin and 34.18% ROE. Recent earnings show mixed results with a Q3 2025 beat but Q4 2025 and Q1 2026 misses. The company maintains robust cash flow from operations and has announced a $0.55 dividend for June 2026. News highlights product innovations like the Schlage Sense Pro smart deadbolt and participation in industry conferences.
Outlook is supported by analyst consensus with a $152.50 price target and no sell ratings, though risks include rising costs and international market weakness. The stock offers growth potential from Americas strength and acquisitions, but investors should monitor margin pressures and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →
